Multiple Sclerosis Journal - Experimental, Translational and Clinical最新文献

{"title":"Coronavirus disease 2019 infection among working-aged people with multiple sclerosis and the impact of disease-modifying therapies.","authors":"Chantelle Murley, Emma Pettersson, Jan Hillert, Alejandra Machado, Emilie Friberg","doi":"10.1177/20552173241248293","DOIUrl":"https://doi.org/10.1177/20552173241248293","url":null,"abstract":"<p><strong>Background: </strong>The risk of coronavirus disease 2019 among people with multiple sclerosis with different disease-modifying therapies is not well established.</p><p><strong>Objective: </strong>To investigate the occurrence of coronavirus disease 2019 and the remaining symptoms among people with multiple sclerosis and the associations with different disease-modifying therapies.</p><p><strong>Methods: </strong>Individuals aged 20-50 listed in the Swedish Multiple Sclerosis Registry were invited to participate in a survey in 2021. Information on reported coronavirus disease 2019 infection and remaining symptoms were linked to individual-level register data. The risks by disease-modifying therapy of having coronavirus disease 2019 or having remaining symptoms were estimated with logistic regression.</p><p><strong>Results: </strong>Of the 4393 participants, 1030 (23.4%) self-reported coronavirus disease 2019 (749 confirmed and 281 suspected). The observed odds for coronavirus disease 2019 did not differ by disease-modifying therapy (<i>p</i>-values <0.05). The majority reporting coronavirus disease 2019 had fully recovered (68.5%), 4.2% were currently/recently sick, and 27.0% had symptoms remaining after 2 months. The most frequently reported remaining symptoms involved one's sense of smell or taste (37.0%), fatigue (20.0%), and breathing (12.0%). No statistically significant associations were observed between having remaining symptoms and the disease-modifying therapy.</p><p><strong>Conclusion: </strong>Despite the initial concerns of differing infection risks by MS treatments, we observed no differences in coronavirus disease 2019 occurrence or remaining symptoms among those who had coronavirus disease 2019. Nonetheless, exercising caution in interpreting our findings, it remains implicit that people with multiple sclerosis are particularly susceptible to infection and that lingering symptoms may persist beyond the initial infection.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 2","pages":"20552173241248293"},"PeriodicalIF":2.8,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11055478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140859816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of dalfampridine in neuromyelitis optica spectrum disorder: A pilot study.","authors":"Jérôme de Seze, Christine Clerc, Matthieu Béreau, Bertrand Bourre, Hélène Zephir, Nicolas Collongues, Laurent Kremer, Patrick Vermersch, Kevin Bigaut","doi":"10.1177/20552173241233952","DOIUrl":"10.1177/20552173241233952","url":null,"abstract":"<p><strong>Objective: </strong>To assess the efficacy of dalfampridine in patients with neuromyelitis optica spectrum disorder.</p><p><strong>Methods: </strong>We included 15 consecutive patients, who were started on a treatment of dalfampridine 10 mg twice daily for 2 weeks. Efficacy assessment was based on walking ability improvement using Timed-25-Foot Walk and 12-item Multiple Sclerosis Walking Scale tests.</p><p><strong>Results: </strong>The mean Timed-25-Foot Walk score was reduced from 14.8 (±2.4) to 11.3 (±1.9) seconds (<i>p</i> = 0.01). The mean score on the 12-item Multiple Sclerosis Walking Scale was reduced from 41.2 (±3.5) to 31.4 (±3.2) (<i>p</i> = 0.004).</p><p><strong>Conclusion: </strong>Dalfampridine seems to be useful for symptomatic treatment of walking impairment in neuromyelitis optica spectrum disorder.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 1","pages":"20552173241233952"},"PeriodicalIF":2.8,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10908237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency of cognitive impairment in patients with neuromyelitis optica spectrum disorder in Mexico.","authors":"Edgar R Valdivia-Tangarife, Fernando Cortés-Enríquez, Alejandra Morlett-Paredes, Teresita Villaseñor-Cabrera, Jorge I Gámez-Nava, Mario A Mireles-Ramírez, Laura González-López, Miguel Á Macías-Islas","doi":"10.1177/20552173241231678","DOIUrl":"10.1177/20552173241231678","url":null,"abstract":"<p><strong>Background: </strong>Between 29% and 67% of neuromyelitis optica spectrum disorder patients have cognitive alterations.</p><p><strong>Objective: </strong>To assess the frequency of cognitive impairment in patients with neuromyelitis optica spectrum disorder in Mexico using the Brief International Cognitive Assessment for Multiple Sclerosis.</p><p><strong>Methods: </strong>We evaluated 40 neuromyelitis optica spectrum disorder patients and 40 healthy controls from Mexico.</p><p><strong>Results: </strong>28 (70.0%) patients with neuromyelitis optica spectrum disorder had cognitive impairment in two or more cognitive domains. Student´s T test showed statistically poor performance by neuromyelitis optica spectrum disorder patients compared to healthy controls on all three neuropsychological test scores. This significant difference was observed on the Symbols Digit Modalities Test (<i>t</i> = 8.875; <i>p</i> ≤ 0.001); California Verbal Learning Test-II memory (<i>t</i> = 10.418; <i>p</i> ≤ 0.001); and Brief Visuospatial Memory Test Revised (<i>t</i> = 6.123; <i>p</i> ≤ 0.001).</p><p><strong>Conclusions: </strong>This study showed that 70% of neuromyelitis optica spectrum disorder patients exhibited cognitive impairment in two or more cognitive domains. Determining the frequency of cognitive impairment will guide the decision of Neuropsychologists in planning cognitive rehabilitation across various domains.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 1","pages":"20552173241231678"},"PeriodicalIF":2.8,"publicationDate":"2024-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10896058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139975484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Superficial white matter integrity in neuromyelitis optica spectrum disorder and multiple sclerosis.","authors":"Darko Komnenić, Owen Robert Phillips, Shantanu H Joshi, Claudia Chien, Tanja Schmitz-Hübsch, Susanna Asseyer, Friedemann Paul, Carsten Finke","doi":"10.1177/20552173231226107","DOIUrl":"10.1177/20552173231226107","url":null,"abstract":"<p><strong>Background: </strong>Superficial white matter (SWM) is a particularly vulnerable area of white matter adjacent to cerebral cortex that was shown to be a sensitive marker of disease severity in several neurological and psychiatric disorders, including multiple sclerosis (MS), but has not been studied in neuromyelitis optica spectrum disorder (NMOSD).</p><p><strong>Objective: </strong>To compare the integrity of SWM between MS patients, NMOSD patients and healthy controls, and explore the correlation of SWM integrity with cognitive performance and overall disability.</p><p><strong>Methods: </strong>Forty NMOSD patients, 48 MS patients and 52 healthy controls were included in the study. Mean diffusivity (MD) values obtained by diffusion tensor imaging were used as a measure of SWM integrity. Cognitive performance and overall disability were assessed with standardized tests.</p><p><strong>Results: </strong>Superficial white matter MD was increased in MS patients compared to healthy controls. Higher MD was associated with poorer spatial memory (most prominently in right temporal and right limbic lobe) and poorer information processing speed in MS patients. After adjusting for age, no significant differences of SWM MD were observed between NMOSD patients and healthy controls.</p><p><strong>Conclusion: </strong>Integrity of SWM is compromised in MS, but not in NMOSD, and can serve as a sensitive marker of disease severity.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 1","pages":"20552173231226107"},"PeriodicalIF":2.5,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10807332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139546682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme.","authors":"T A Hardy, P Aouad, M H Barnett, S Blum, S Broadley, W M Carroll, D Crimmins, D Griffiths, S Hodgkinson, J Lechner-Scott, A Lee, R Malhotra, P McCombe, J Parratt, C Plummer, A Van der Walt, K Martel, R A Walker","doi":"10.1177/20552173231226106","DOIUrl":"10.1177/20552173231226106","url":null,"abstract":"<p><strong>Background: </strong>Siponimod is approved for use in people with secondary progressive multiple sclerosis (pwSPMS). An integrated digital platform, MSGo, was developed for pwSPMS and clinicians to help navigate the multiple steps of the pre-siponimod work-up.</p><p><strong>Objective: </strong>To explore real-world onboarding experiences of siponimod amongst pwSPMS in Australia.</p><p><strong>Methods: </strong>Retrospective, non-interventional, longitudinal, secondary analysis of data extracted from MSGo (20 April 2022). The primary endpoint was the average time for siponimod onboarding; secondary endpoints were adherence and sub-group analyses of variables influencing onboarding.</p><p><strong>Results: </strong>Mixed-cure modelling estimated that 58% of participants (<i>N</i> = 368, females 71%, median age of 59 years) registered in MSGo would ever initiate siponimod. The median time to initiation was 56 days (95% CI [47-59] days). Half of the participants cited 'waiting for vaccination' as the reason for initiation delay. Cox regression analyses found participants with a nominated care partner had faster onboarding (HR 2.1, 95% CI [1.5-3.0]) and were more likely to continue self-reporting daily siponimod dosing than were those without a care partner (HR 2.2, 95% CI [1.3-3.7]).</p><p><strong>Conclusions: </strong>Despite the limitations of self-reported data and the challenges of the COVID-19 pandemic, this study provides insights into siponimod onboarding in Australia and demonstrates the positive impact of care partner support.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 1","pages":"20552173231226106"},"PeriodicalIF":2.8,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10787529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dairy and gluten in disease activity in multiple sclerosis.","authors":"Isabel A Temperley, Alexandra N Seldon, Madeline Aw Reckord, Claudia A Yarad, Farihah T Islam, Kerith Duncanson, Rodney A Lea, Jeannette Lechner-Scott, Vicki E Maltby","doi":"10.1177/20552173231218107","DOIUrl":"10.1177/20552173231218107","url":null,"abstract":"<p><strong>Background: </strong>Many diets promoted specifically for multiple sclerosis have been suggested to improve disease activity. Dairy and gluten are two components for which the recommendations vary between these diets. Existing research into the association between these dietary components and disease activity has been conflicting.</p><p><strong>Objective: </strong>To explore the relationship between dairy and gluten intake and disease activity in multiple sclerosis over a 2-year period, using no evidence of disease activity (NEDA) 3 status.</p><p><strong>Methods: </strong>186 participants' dairy and gluten intake was retrospectively estimated over 2 years using a dairy and gluten dietary screener. Estimated dairy and gluten intake was compared to disease activity, indicated by no evidence of disease activity 3 status, and quality of life, assessed by the Multiple Sclerosis International Quality of Life (MusiQoL) questionnaire.</p><p><strong>Results: </strong>No significant association was found between mean estimated dairy or gluten intake and NEDA 3 status (<i>p</i> = 0.15 and 0.60, respectively). Furthermore, there was no significant relationship between dairy or gluten intake and MusiQoL) scores (<i>p</i> = 0.11 and 0.51, respectively).</p><p><strong>Conclusion: </strong>Whilst we cannot rule out modest benefits due to our small sample size, we found that neither dairy nor gluten intake was associated with disease activity or quality of life in this study.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 4","pages":"20552173231218107"},"PeriodicalIF":2.8,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10734333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138830613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The six spot step test is superior in detecting walking capacity impairments compared to short- and long-distance walk tests in persons with multiple sclerosis.","authors":"Anders G Skjerbæk, Ulrik Dalgas, Egon Stenager, Finn Boesen, Lars G Hvid","doi":"10.1177/20552173231218127","DOIUrl":"https://doi.org/10.1177/20552173231218127","url":null,"abstract":"<p><strong>Background: </strong>Walking capacity is important not only to persons with multiple sclerosis but also to clinical practice and research. The present study aims to compare the extent of impairments (relative to healthy controls) across three commonly used walking capacity outcomes in persons with multiple sclerosis.</p><p><strong>Methods: </strong>In a two-hospital cross-sectional study, walking capacity was assessed using the timed-25-footwalk-test (timed 25-ft walk test; 'walking speed'), the six-minute-walk-test ('walking endurance') and the six-spot-step-test ('walking balance and coordination'). Data were compared to normative reference data in healthy controls.</p><p><strong>Results: </strong>A total of 228 persons with multiple sclerosis (68% females) were involved in the study: age 53.7 ± 11.6 y (range 26-81 y); patient-determined-disease-steps 3 [IQR; 1; 4] (range 0-7); time since diagnosis 12.6 ± 9.9 y (range 0-49 y); MS-phenotype (relapse remitting MS, secondary progressive MS, primary progressive MS) 146/39/41; and co-morbidity <i>n</i> = 80 (35%). Compared to healthy controls, deficits were observed across all walking capacity outcomes (<i>p </i>< 0.001): timed 25-foot walk test -26 [-30; -23]%, 6 minute-walk-test -36 [-39; -32]% and six-spot-step-test -44 [-47; -40]%. Deficits differed across walking capacity outcomes (<i>p </i>< 0.001).</p><p><strong>Conclusion: </strong>Altogether, persons with multiple sclerosis performed substantially worse than healthy controls across all three walking capacity outcomes. The results showed that the six-spot-step-test was superior to the timed 25-foot walk test and the 6 minute-walk-test in detecting walking capacity impairments in persons with multiple sclerosis.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 4","pages":"20552173231218127"},"PeriodicalIF":2.8,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10722939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138808012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Humoral immune response after Ad26.COV2.S vaccination in patients with multiple sclerosis treated with natalizumab","authors":"M. Gudesblatt, Myassar Zarif, Barbara Bumstead, M. Buhse, Olivia Kaczmarek, Hanyue Li, Zhaonan Sun, Nicole Scott, Jason P Mendoza, Robin L Avila","doi":"10.1177/20552173231218117","DOIUrl":"https://doi.org/10.1177/20552173231218117","url":null,"abstract":"The immunomodulatory effects of disease-modifying therapies for multiple sclerosis might affect the immune response to vaccines for severe acute respiratory syndrome coronavirus 2. We analyzed the severe acute respiratory syndrome coronavirus 2-specific antibody response and lymphocyte profile before and after Ad26.COV2.S (Johnson & Johnson) vaccination in natalizumab-treated patients with multiple sclerosis. There was a 72-fold increase in mean anti-severe acute respiratory syndrome coronavirus 2 spike immunoglobulin G levels 4 weeks after vaccination and a 137-fold increase after 6 months. Other immune signals were within normal ranges. Natalizumab-treated patients with multiple sclerosis had a robust immune response to Ad26.COV2.S vaccine, and other immune signals were not significantly affected.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"3 3","pages":""},"PeriodicalIF":2.8,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138585100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diet-induced changes in functional disability are mediated by fatigue in relapsing-remitting multiple sclerosis: A secondary analysis of the WAVES randomized parallel-arm trial.","authors":"Landon J Crippes, Solange M Saxby, Farnoosh Shemirani, Babita Bisht, Christine Gill, Linda M Rubenstein, Patrick Ten Eyck, Lucas J Carr, Warren G Darling, Karin F Hoth, John Kamholz, Linda G Snetselaar, Tyler J Titcomb, Terry L Wahls","doi":"10.1177/20552173231209147","DOIUrl":"10.1177/20552173231209147","url":null,"abstract":"<p><strong>Background: </strong>People with multiple sclerosis (MS) often report dietary modifications; however, evidence on functional outcomes remains sparse.</p><p><strong>Objective: </strong>Evaluate the impact of the low-saturated fat (Swank) and modified Paleolithic elimination (Wahls) diets on functional disability among people with relapsing-remitting MS.</p><p><strong>Methods: </strong>Baseline-referenced MS functional composite (MSFC) scores were calculated from nine-hole peg-test (NHPT), timed 25-foot walk, and oral symbol digit modalities test (SDMT-O) collected at four study visits: (a) run-in, (b) baseline, (c) 12 weeks, and (d) 24 weeks. Participants were observed at run-in and then randomized at baseline to either the Swank (<i>n</i> = 44) or Wahls (<i>n</i> = 43) diets.</p><p><strong>Results: </strong>Among the Swank group, MSFC scores significantly increased from -0.13 ± 0.14 at baseline to 0.10 ± 0.11 at 12 weeks (<i>p</i> = 0.04) and 0.14 ± 0.11 at 24 weeks (<i>p</i> = 0.02). Among the Wahls group, no change in MSFC scores was observed at 12 weeks from 0.10 ± 0.11 at baseline but increased to 0.28 ± 0.13 at 24 weeks (<i>p</i> = 0.002). In both groups, NHPT and SDMT-O z-scores increased at 24 weeks. Changes in MSFC and NHPT were mediated by fatigue.</p><p><strong>Discussion: </strong>Both diets reduced functional disability as mediated by fatigue.</p><p><strong>Trial registration: </strong>Clinicaltrials.gov Identifier: NCT02914964.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 4","pages":"20552173231209147"},"PeriodicalIF":2.5,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617283/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71425202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortality of neuromyelitis optica spectrum disorder patients in an Argentinean population: A study from the RelevarEM registry.","authors":"Edgar Carnero Contentti,&nbsp;Pablo A Lopez,&nbsp;Juan Pablo Pettinicchi,&nbsp;Juan Criniti,&nbsp;Agustín Pappolla,&nbsp;Jimena Miguez,&nbsp;Edgardo Cristiano,&nbsp;Liliana Patrucco,&nbsp;Susana Liwacki,&nbsp;Verónica Tkachuk,&nbsp;María E Balbuena,&nbsp;Carlos Vrech,&nbsp;Norma Deri,&nbsp;Jorge Correale,&nbsp;Mariano Marrodan,&nbsp;María C Ysrraelit,&nbsp;Felisa Leguizamon,&nbsp;Geraldine Luetic,&nbsp;María L Menichini,&nbsp;Darío Tavolini,&nbsp;Carolina Mainella,&nbsp;Gisela Zanga,&nbsp;Marcos Burgos,&nbsp;Javier Hryb,&nbsp;Andrés Barboza,&nbsp;Luciana Lazaro,&nbsp;Ricardo Alonso,&nbsp;Nora Fernández Liguori,&nbsp;Débora Nadur,&nbsp;Marina Alonso Serena,&nbsp;Alejandro Caride,&nbsp;Friedemann Paul,&nbsp;Juan I Rojas","doi":"10.1177/20552173231205444","DOIUrl":"https://doi.org/10.1177/20552173231205444","url":null,"abstract":"<p><p>We aimed to evaluate mortality and causes of death among Argentinean neuromyelitis optica spectrum disorder (NMOSD) patients and identify predictors of death. Retrospective study included 158 NMOSD patients and 11 (7%) patients died after 11 years of follow-up for a total exposure time of 53,345 days with an overall incidence density of 2.06 × 10.000 patients/day (95% CI 1.75-2.68). Extensive cervical myelitis with respiratory failure (45%) was the most frequent cause of death. Older age (HR = 2.05, <i>p</i> = 0.002) and higher disability score (HR = 2.30, <i>p</i> < 0.001) at disease onset were independent predictors of death. We found an 11-year mortality rate of 7% in Argentinean NMOSD patients.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 4","pages":"20552173231205444"},"PeriodicalIF":2.8,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/68/4c/10.1177_20552173231205444.PMC10580714.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49679895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}